Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 6/20 | 1.00 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL371514 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL247045 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL29885626 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL371512 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL21348880 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL371511 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL14007131 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL15926078 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL10824967 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI | |
| SCHEMBL11348573 | 1.00 | GBA1 (1.00) | GBA1FUCA1LMNAAPPSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023072971-A2 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-05-04 | — | — | WO | disclosed |
| EP-4170347-A1 | GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-20120093875-A1 | AMINOCYCLITOL COMPOUNDS, PROCESS FOR OBTAINING THEM AND USES | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2012-04-19 | — | — | US | disclosed |
| EP-2409966-A1 | AMINOCYCLITOL COMPOUNDS, PROCEDURE FOR THE OBTAINMENT AND USES | Consejo Superior de Investigaciones Científicas (CSIC) (ES) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120093875-A1 | AMINOCYCLITOL COMPOUNDS, PROCESS FOR OBTAINING THEM AND USES | AADAT, NFATC1, PBK | GBA1 112/4885FUCA1 263/4885LMNA 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.